• PharmaMar secured regulatory clearances in Canada, Qatar, South Korea for Zepzelca with Roche’s Tecentriq as first-line maintenance in ES-SCLC.
• Use targets adults without progression after induction with Tecentriq, carboplatin, etoposide; decision backed by Phase 3 IMforte1 results.
• Authorization lifts the regimen’s footprint to 18 territories worldwide, including the EU, US.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharma Mar SA published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.